

H2
sub
I 6
58. (Amended) An isolated antibody, or fragment thereof, specifically immunoreactive with a p16 protein that specifically binds to a cyclin-dependant kinase.

H3
59. (Amended) The antibody of claim 58, wherein the antibody is specifically immunoreactive with a cell cycle regulatory (CCR) protein which is encoded by a nucleic acid that hybridizes at conditions of 2.0 x SSC at 50 °C or higher stringency to a nucleotide sequence of SEQ ID No: 1.

H4
60. (Amended) The antibody of claim 58, wherein the p16 protein has an amino acid sequence of SEQ ID No: 2.

N.E.
Duplicate
61. (Reiterated) The antibody of any one of claims 58, 59 or 60, wherein the antibody is a monoclonal antibody.

62. (Reiterated) The antibody of any one of claims 58, 59 or 60, wherein the antibody is a Fab fragment.

63. (Reiterated) The antibody of any one of claims 58, 59 or 60, wherein the antibody is a F(ab')₂ fragment.

64. (Reiterated) The antibody of claim 58, wherein the antibody is labeled with a detectable label.

H5
65. (Twice Amended) A purified preparation of a polyclonal antibody, or fragment thereof, specifically immunoreactive with a p16 protein of SEQ ID No. 2.

sub
I 8
66. (Twice Amended) A purified preparation of a polyclonal antibody, or fragment thereof, specifically immunoreactive with a p16 protein encoded by a nucleic acid that hybridizes at conditions of 2.0 x SSC at 50 °C or higher stringency to a nucleotide sequence of SEQ ID No. 1.

H6
67. (Amended) The preparation of claim 66, wherein the p16 protein has an amino acid sequence of SEQ ID No: 2.

H 7 315 19
68. (Amended) A kit for detecting a cell cycle regulatory (CCR) protein comprising (i) an isolated anti-CCR antibody, or fragment thereof, specifically immunoreactive with a p16 protein, and (ii) a detectable label for detecting the anti-CCR antibody in immunocomplexes with a cell cycle regulatory (CCR) protein.

69. (Reiterated) The kit of claim 68, wherein means for detecting the anti-CCR antibody is a detectable label conjugated with the anti-CCR antibody.

N.E. Duplicate
70. (Reiterated) The kit of claim 68, wherein means for detecting the anti-CCR antibody is a second antibody immunoreactive with the anti-CCR antibody.

H 8
71. (Amended) The kit of claim 68, wherein the p16 protein has an amino acid sequence of SEQ ID No. 2.

N.E. Duplicate
72. (Reiterated) The kit of claim 68, wherein the antibody is a monoclonal antibody.

73. (Reiterated) The kit of claim 69, wherein the antibody is a purified preparation of polyclonal antibodies.

H 9
74. (Amended) The kit of claim 68, wherein the antibody is a Fab fragment.

N.E. Duplicate
75. (Reiterated) The kit of claim 68, wherein the antibody is a F(ab')₂ fragment.

H 10
76. (Amended) The kit of claim 68, wherein the antibody is provided in a form suitable for detecting the cell cycle regulatory (CCR) protein in samples in cells.

H 11
77. (Amended) The preparation of claim 11, wherein the p16 protein is identical to SEQ ID No. 2.

Please add the following new claims:

- 12
14
79. (New) The antibody of claim 58, wherein the p16 protein is a human protein.
80. (New) The preparation of claim 66, wherein the p16 protein is a human protein.
81. (New) The preparation of claim 11, wherein the p16 protein is a human protein.
82. (New) The kit of claim 68, wherein the p16 protein is a human protein.

The claims presented above incorporate changes as indicated by the marked-up versions below.

11. (Twice Amended) An antibody preparation specifically reactive with [an epitope of an immunogen comprising a substantially pure preparation of] a [cell regulatory (CCR)] p16 protein [or a fragment thereof which] that specifically binds to a cyclin-dependent kinase (CDK)[, the full length form of said CCR-protein having an approximate molecular weight in the range of 14.5kD to 16kD, in an immunogenic preparation, said immunogen being capable of eliciting and immune response specific for said CCR-protein]

58. (Amended) An isolated antibody, or fragment thereof, specifically immunoreactive with a [cell cycle regulatory (CCR)] p16 protein[, wherein said protein comprises at least four ankyrin-repeats and] that specifically binds to a cyclin-dependant kinase.

59. (Amended) The antibody of claim 58, wherein the antibody is specifically immunoreactive with a cell cycle regulatory (CCR) protein which is encoded by a nucleic acid [wherein said nucleic acid] that hybridizes at conditions of 2.0 x SSC at 50 °C or higher stringency to a nucleotide sequence of SEQ ID No[s]: 1[, 3, or 5].

2

60. (Amended) The antibody of claim 58, wherein the [antibody is specifically immunoreactive with an cell cycle regulatory (CCR) protein comprising] p16 protein has an amino acid sequence of SEQ ID No[s]: 2[, 4, or 6].

61. (Reiterated) The antibody of any one of claims 58, 59 or 60, wherein the antibody is a monoclonal antibody.
62. (Reiterated) The antibody of any one of claims 58, 59 or 60, wherein the antibody is a Fab fragment.
63. (Reiterated) The antibody of any one of claims 58, 59 or 60, wherein the antibody is a F(ab')₂ fragment.
64. (Reiterated) The antibody of claim 58, wherein the antibody is labeled with a detectable label.
65. (Twice Amended) A purified preparation of a polyclonal antibody [antibodies], or fragment[s] thereof, specifically immunoreactive with a [cell cycle regulatory (CCR)] p16 protein [at least 80% identical to any one] of SEQ ID No[s]. 2[, 4, or 6].
66. (Twice Amended) A purified preparation of a polyclonal antibody [antibodies], or fragment[s] thereof, specifically immunoreactive with a [cell cycle regulatory (CCR)] p16 protein[, wherein the antibody is specifically immunoreactive with a cell cycle regulatory (CCR) protein which is] encoded by a nucleic acid [wherein said nucleic acid] that hybridizes at conditions of 2.0 x SSC at 50 °C or higher stringency to a nucleotide sequence of SEQ ID No[s]. 1[, 3, or 5].
67. (Amended) The preparation of claim 66, wherein the [antibody is specifically immunoreactive with cell cycle regulatory (CCR)] p16 protein [comprising] has an amino acid sequence of SEQ ID No[s]: 2[, 4, or 6].
68. (Amended) A kit for detecting a cell cycle regulatory (CCR) protein comprising (i) an isolated anti-CCR antibody, or fragment thereof, specifically immunoreactive with a [cell cycle regulatory (CCR)] p16 protein, and (ii) a detectable label for detecting the anti-CCR antibody in immunocomplexes with a cell cycle regulatory (CCR) protein.